Release Date: May 01, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you clarify what you mean by localizing production in response to tariffs? Are you building new capacity in the US? A: James Lico, President and CEO, explained that Fortive has been derisking its supply chain over the years without significant new investments. The company is accelerating existing plans to reduce reliance on China, focusing on contract manufacturing and current facilities rather than building new capacity.
Q: Why is the Test and Measurement segment experiencing such a significant decline? Is this due to delayed demand or a more permanent issue? A: James Lico noted that the decline is due to customers delaying investments amid economic uncertainty, particularly in semiconductors and electronics. The company expects recovery to be pushed into 2026, with improvements anticipated throughout the year.
Q: How are tariffs impacting Fortive's financial outlook for the year, and what mitigation strategies are in place? A: Elena Rosman, VP of Investor Relations, stated that the estimated tariff impact is around $200 million for 2025, with plans to offset about 80% through pricing and other countermeasures. Full mitigation is expected by the fourth quarter of 2025.
Q: Can you provide more detail on the performance and outlook for the Advanced Healthcare Solutions (AHS) segment? A: Elena Rosman mentioned that AHS margins typically start lower in Q1 and improve throughout the year. The segment faced FX headwinds and fewer days impacting consumables, but growth investments are expected to support margin expansion as the year progresses.
Q: What are the expectations for Fortive's regional sales performance, particularly in North America, China, and Western Europe? A: James Lico highlighted that North America is expected to be the strongest market, with good performance across various segments. China is anticipated to be down high single digits for the year, while Western Europe faces challenges, particularly in the Precision Technologies segment.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。